TrialThe New England journal of medicine2018
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Robert J Motzer et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2,545 papers cite itlatest 60 shown
this paperpooled ittrialcites it